216 related articles for article (PubMed ID: 32099055)
1. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma.
Dong MP; Enomoto M; Thuy LTT; Hai H; Hieu VN; Hoang DV; Iida-Ueno A; Odagiri N; Amano-Teranishi Y; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2020 Feb; 10(1):3392. PubMed ID: 32099055
[TBL] [Abstract][Full Text] [Related]
2. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.
Odagiri N; Hai H; Thuy LTT; Dong MP; Suoh M; Kotani K; Hagihara A; Uchida-Kobayashi S; Tamori A; Enomoto M; Kawada N
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722224
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies.
Gorgulho J; Roderburg C; Heymann F; Schulze-Hagen M; Beier F; Vucur M; Kather JN; Laleh NG; Tacke F; Brümmendorf TH; Luedde T; Loosen SH
Int J Cancer; 2021 Sep; 149(5):1189-1198. PubMed ID: 33890289
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
6. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
8. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
9. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Iida-Ueno A; Enomoto M; Uchida-Kobayashi S; Hagihara A; Teranishi Y; Fujii H; Morikawa H; Murakami Y; Tamori A; Thuy LTT; Kawada N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):857-864. PubMed ID: 30178114
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
Kim HJ; Park S; Kim KJ; Seong J
Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
[TBL] [Abstract][Full Text] [Related]
11. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
12. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
13. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
[TBL] [Abstract][Full Text] [Related]
15. sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection.
Jubel JM; Randau TM; Becker-Gotot J; Scheidt S; Wimmer MD; Kohlhof H; Burger C; Wirtz DC; Schildberg FA
Front Immunol; 2021; 12():687065. PubMed ID: 34421900
[TBL] [Abstract][Full Text] [Related]
16. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
Future Oncol; 2019 Jun; 15(16):1811-1822. PubMed ID: 30969136
[TBL] [Abstract][Full Text] [Related]
17. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.
Chu SS; Kuo YH; Liu WS; Wang SC; Ho CH; Chen YC; Yang CC; Wu HC
Sci Rep; 2021 Jan; 11(1):1614. PubMed ID: 33452421
[TBL] [Abstract][Full Text] [Related]
18. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer.
Liu C; Li X; Li A; Zou W; Huang R; Hu X; Yu J; Zhang X; Yue J
J Immunol Res; 2022; 2022():9621466. PubMed ID: 35419462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
